The life sciences company, ForteBio, has launched its Dip and Read Protein G biosensor, designed for the fast-track analysis of specific biomolecular interactions of various types of the antibody molecule, mammalian immunoglobulin.
DSM Pharma Chemicals, a business unit of DSM Pharmaceutical Products, has announced the launch of InnoSyn route scouting services, meeting pharma needs to outsource process development R&D.
Drugmakers may soon have a soon be able to identify fake pharmaceuticals using a new technique based on principals originally developed to detect explosives
ADME/toxicity testing firm Cyprotexservice providers is bringing researchers free online access to its database of ADME and pharmacokinetic properties of marketed drugs, through Cloe Knowledge.
Indian drugmaker Cipla may invest in South Africa’s Cipla Medpro to boost manufacturing capacity and improve access to rapidly expanding African pharmaceutical markets.
Patient recruiters and national regulators must learn from each other to better understand outreach tactics and how they fit with a country’s ethics and laws.
Outsourcing-Pharma presents its latest round up of movements in the pharma outsourcing sector, including appointments at PharmaNet, Kendle, Synexus and Gene Logic.
Drug delivery company Monosol Rx and partner Reckitt Benckiser Pharmaceuticals have received US Food and Drug Administration (FDA) clearance to market a sublingual film formulation of the opioid dependence treatment Suboxone.
Aspect Magnetic Technologies claim its new compact M2 magnetic resonance imaging (MRI) systems “help preclinical researchers expand the horizons for completely new ideas and discovery.”
US formulation services provider Bend Research has received a new patent for the process of producing spray-dried solid amorphous dispersions of drugs using single-fluid pressure nozzles.
RecipharmCobra Biologics has received US and EU patent protection for an antibiotic resistance gene-free plasmid maintenance technology it claims can boost biomanufacturing yields.
NanGenex is introducing GMP bench-top and pilot plant reactors to scale-up its process for the continuous production of nanostructured active ingredients.
Retention strategies, trial site evaluations and dedicated budgets should be used to recruit patients to, and keep them in, clinical trials, according to research.
Tracking “non-content” metadata is an important part of any pharmaceutical submission, yet many drugmakers fail to take an integrated approach to the task according to regulatory expert Kate Wilber.
Syringe maker Unilife said it was hit by falling revenues, costs of US relocation and workforce expansion in Q4, but that significant business progress was made in fiscal 2010.
Xcelience and IriSys have formed a joint venture to help streamline access to chemistry manufacturing and controls (CMC) and regulatory expertise for North American pharmaceutical and biotechnology companies.
Outsourcing-Pharma presents its latest round up of movements in the pharma outsourcing sector, including appointments at PPD, Coldstream Laboratories and MPI Research.
Cell culture, LAIV vaccines and recombinant DNA technology should be supported by the US government as part of a long-term overhaul of pandemic response capabilities, according to PCAST.
Biomarkers are critical to discovery and can help pharmaceutical firms make development a more efficient and cost effective process accord to bioanalysis services provider KCAS.
ZRG Partners says there was a “fight for talent” in hiring, firing and vacancies in Q2, with the outsourcing and pharmaceutical sectors battling for employees within regulatory, quality and clinical roles.
Aterovax has teamed up with Biomnis to target the clinical trial industry with a new atherosclerosis biomarker, sPLA2, designed to give researchers better insight into a candidate heart drug’s therapeutic potential.
in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including appointments at Discovery Labs, NewAge Industries and Jennerex.
Almac says an effective biomarker strategy boosts a drug candidates’ chance of success and can ultimately add value to a developer’s business by opening door to diagnostics.
India is considering strengthening compulsory licensing provisions, which allow third parties to produce patented products, in response to concerns about overseas takeovers and drug prices.
Stirling Pharma’s state-of-the-art Canadian plant will open its doors in late September, and first to come off the production line will be the drug, acetaminophen.
